| scholarly article | Q13442814 |
| P50 | author | Deepak L. Bhatt | Q47264894 |
| Alexandre Abizaid | Q101042967 | ||
| Andréa Abizaid | Q106729229 | ||
| Martin B. Leon | Q112156984 | ||
| P2093 | author name string | Spencer B King | |
| Rodolfo Staico | |||
| Eduardo L Nicolela | |||
| Ricardo A Costa | |||
| Marco A Perin | |||
| André Labrunie | |||
| Décio Salvadori | |||
| Fausto Feres | |||
| Fernando S Devito | |||
| George X Meireles | |||
| Hélio J Castello | |||
| J Antônio Marin-Neto | |||
| J Eduardo T de Paula | |||
| J Ribamar Costa | |||
| José A Mangione | |||
| Juliana P de Castro | |||
| Manuela Negoita | |||
| Marcos Gusmão | |||
| Minglei Liu | |||
| OPTIMIZE Trial Investigators | |||
| Roberto V Botelho | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2510-2522 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial | |
| P478 | volume | 310 |
| Q89490251 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repre |
| Q34046881 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres |
| Q42134079 | 3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. |
| Q26784131 | A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents |
| Q31043715 | Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey |
| Q38824035 | Antiplatelet Management for Coronary Heart Disease: Advances and Challenges |
| Q38535999 | Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation |
| Q47657861 | Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications |
| Q52593614 | Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. |
| Q35324208 | Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. |
| Q35783499 | Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial |
| Q43501114 | Antiplatelet therapy: DAPT for 3 months is sufficient |
| Q90380295 | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| Q28072522 | Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation |
| Q51471743 | Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. |
| Q88786608 | Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017 |
| Q36347982 | Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. |
| Q35530065 | Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents |
| Q85555592 | Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015? |
| Q38629852 | Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. |
| Q36369122 | Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction |
| Q61796915 | Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials |
| Q39288609 | Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study |
| Q35210009 | Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial |
| Q57475594 | Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management |
| Q38194095 | Choosing the right coronary stent in the modern era. |
| Q40908174 | Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. |
| Q40580110 | Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors |
| Q34055438 | Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study |
| Q58614119 | Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction |
| Q38591868 | Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal? |
| Q36285820 | Current Practices Regarding Perioperative Management of Patients With Fracture on Antiplatelet Therapy: A Survey of Orthopedic Surgeons. |
| Q38578616 | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents |
| Q38362982 | Current antiplatelet agents: place in therapy and role of genetic testing |
| Q61804282 | De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review |
| Q92211505 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention |
| Q92214029 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk |
| Q33613297 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention |
| Q64243686 | Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease |
| Q53840073 | Do non-inferiority trials of reduced intensity therapies show reduced effects? A descriptive analysis. |
| Q43118597 | Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. |
| Q93198626 | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| Q38635747 | Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies |
| Q52813379 | Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment. |
| Q41111747 | Dual antiplatelet therapy duration after drug-eluting stents: how long? |
| Q30910604 | Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data? |
| Q42650020 | Dual antiplatelet therapy for secondary prevention of coronary artery disease. |
| Q38261199 | Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions |
| Q90213322 | Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis |
| Q42369292 | Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine |
| Q41960465 | Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. |
| Q93115066 | Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis |
| Q38751834 | Duration of dual antiplatelet therapy in acute coronary syndrome |
| Q33642986 | Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion. |
| Q91751227 | Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis |
| Q28552288 | Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy |
| Q50216134 | Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography |
| Q93011947 | Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial |
| Q91886818 | Effect of Statin Therapy on Outcomes of Patients With Acute Ischemic Stroke and Atrial Fibrillation |
| Q89976942 | Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians |
| Q36237726 | Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis. |
| Q55282779 | Efficacy and safety of short-term (≤6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials. |
| Q36682317 | Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines |
| Q38297800 | Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration |
| Q35283386 | Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis |
| Q26771864 | Hemostatic management of patients undergoing ear-nose-throat surgery |
| Q40859061 | How long should dual antiplatelet therapy be continued following implantation of drug eluting stents? |
| Q89682110 | Impact of early (3 months) dual antiplatelet treatment interruption prior to renal transplantation in patients with second-generation DES on perioperative stent thrombosis and MACEs |
| Q38860495 | Is it time to take bare metal stents off the catheter laboratory shelf? |
| Q39093174 | Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. |
| Q35991815 | Management of the patient with an acute coronary syndrome using oral anticoagulation |
| Q88195712 | Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation |
| Q61401768 | Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris |
| Q42369331 | New guidelines on duration of dual antiplatelet therapy in patients with coronary artery disease: what's the novelty? |
| Q53256913 | New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation. |
| Q42340613 | Non-cardiac surgery following drug-eluting coronary stent implantation-a question of timing? |
| Q90634760 | One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation |
| Q37043053 | One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium ste |
| Q50437651 | Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation |
| Q26852812 | Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer? |
| Q92099516 | Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent |
| Q59811532 | Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome |
| Q47136631 | Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. |
| Q44588219 | Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome : Practical lessons from a review |
| Q35541045 | Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials |
| Q55311019 | Optimal duration of dual antiplatelet therapy for coronary artery disease. |
| Q38176288 | Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation |
| Q37522553 | Organ transplantation and drug eluting stents: Perioperative challenges |
| Q30239889 | Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression |
| Q36086140 | Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease |
| Q88195597 | Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy |
| Q38631422 | Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitors |
| Q38433830 | Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation |
| Q57154436 | Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations |
| Q37070397 | Pregnancy in women after coronary revascularization |
| Q41028031 | Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials |
| Q92929839 | Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence |
| Q92093210 | Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT t |
| Q35626702 | Recent advances in the diagnosis and treatment of acute myocardial infarction |
| Q36624476 | Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials |
| Q30241829 | Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials |
| Q51739975 | Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. |
| Q55402932 | Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. |
| Q36117653 | Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies |
| Q38970275 | Single or dual antiplatelet therapy after PCI. |
| Q41083785 | Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis |
| Q41607661 | Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice |
| Q26785321 | Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 |
| Q56531048 | Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) t |
| Q55431233 | The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". |
| Q38687494 | The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents |
| Q93379481 | The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short |
| Q42333644 | The optimal duration of dual antiplatelet therapy after implantation of drug-eluting coronary stents: an unanswered question. |
| Q35070809 | Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis |
| Q31155795 | Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients |
| Q26866350 | Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy |
| Q88195708 | Twelve Months Dual Antiplatelet Therapy after Drug-eluting Stents - Too Long, too Short or Just Right? |
| Q35783487 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents |
| Q51072241 | Ultra-hydrophilic stent platforms promote early vascular healing and minimise late tissue response: a potential alternative to second-generation drug-eluting stents. |
| Q49723078 | Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial. |
| Q86014270 | [ESC/EACTS guidelines on myocardial revascularization : Amendments 2014] |
Search more.